Company Developments - Insulet Corp. announced the availability of its Omnipod 5 Automated Insulin Delivery system in France, integrated with Dexcom's G6 sensor, and launched the system with G7 compatibility in the United States [1][5] - The Omnipod 5 App for iPhone has been released in a limited market, making Insulet the first company to offer a tubeless AID system fully controllable from a smartphone [3][9] - The Omnipod 5 system is now available for individuals aged two years and above with Type 1 diabetes, and it has received reimbursement status from the French National Authority for Health [8] Market Insights - The global insulin delivery devices market was valued at $12.5 billion in 2021 and is projected to grow at a CAGR of 7.4% by 2030 [4][10] - The increasing prevalence of diabetes due to aging, obesity, and unhealthy lifestyles is driving demand for advanced insulin delivery devices [10] Competitive Landscape - Insulet's Omnipod 5 system is compatible with both Dexcom G6 and Abbott's FreeStyle Libre 2 Plus CGM sensors, expanding its market reach in Europe [5][8] - Insulet's stock has seen a decline of 31.1% over the past year, contrasting with the industry's decline of 1.7% [12] Recent Clinical Results - Positive results from a randomized controlled trial (OP5-003) demonstrated improved glycemic and patient-reported outcomes in Type 1 diabetes patients using Omnipod 5, showing its superiority over standard pump therapy [20]

Insulet Corporation (PODD) is primed for growth in the coming quarters as its revolutionary Omnipod 5 offering continues to successfully drive market growth. The company is making remarkable progress in terms of its key strategic imperatives to help patients in their diabetes management. Sound financial stability further instills optimism. The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $13.46 billion. Insulet projects a long-term estimated earnings gro ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style ...

Insulet Corporation (PODD) reported GAAP earnings per share (EPS) of 73 cents for first-quarter 2024, which significantly improved from the year-ago period's EPS of 34 cents. The figure also exceeded the Zacks Consensus Estimate by 87.2%. First-quarter 2023 adjusted earnings per share were 23 cents. Revenues Revenues in the first quarter totaled $441.7 million, beating the Zacks Consensus Estimate by 4.3%. The top line jumped 23.3% year over year (up 22.8% at the constant exchange rate or CER). CER growth e ...

Forward Looking Statement Risks and uncertainties include, but are not limited to our dependence on a principal product platform; the impact of competitive products, technological change and product innovation; our ability to maintain an effective sales force and expand our distribution network; our ability to maintain and grow our customer base; our ability to scale the business to support revenue growth; our ability to secure and retain adequate coverage or reimbursement from third-party payors; the impac ...

Insulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and Chief Executive Officer Ana Maria Chadwick - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Margaret Kaczor - William Blair Robbie Marcus - JP Morgan Jeff Johnson - Baird Michael Polark - Wolfe Research Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Patric ...

Insulet (PODD) reported $441.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 23.4%. EPS of $0.73 for the same period compares to $0.23 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $423.52 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +87.18%, with the consensus EPS estimate being $0.39.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2024 OR Washington, D.C. 20549 _____________________________________________________ Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name of ...

Exhibit 99.1 Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue and Operating Margin Guidance ACTON, Mass. - May 9, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended March 31, 2024. ® First Quarter Financial Highlights: Recent Strategic Highlights: See description of non-GAAP financial measure ...

Analysts on Wall Street project that Insulet (PODD) will announce quarterly earnings of $0.39 per share in its forthcoming report, representing an increase of 69.6% year over year. Revenues are projected to reach $423.52 million, increasing 18.3% from the same quarter last year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this perio ...